The development of monoclonal antibodies that recognize tumor-associated antigens has led to significantly greater practical possibilities for producing highly specific radiolabeled antibodies for diagnosis and therapy of human tumors. A number of problems remain before this technique will be ready for routine clinical application however. Achieving the high target to background ratio that are predicted on theoretical grounds is a major challenge in cancer investigation.